Author:
McMahon-Pratt D.,Kima P.E.,Soong L.
Reference41 articles.
1. Greenblatt, C.L. (1980) in New Developments with Human and Veterinary Vaccines (Mezrahi, I. et al., eds), pp 259–285, Liss
2. Development of a safe live Leishmania vaccine by gene replacement;Titus;Proc. Natl. Acad. Sci. U. S. A,1995
3. Characterization of human T lymphocyte mediated immune responses induced by a vaccine against American tegumentary leishmaniasis;Mendonça;Am. J. Trop. Med. Hyg,1995
4. Immune responses in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: skin reactivity, T-cell proliferation and interferon-gamma production;Castes;Vaccine,1994
5. Oral Salmonella typhimirium (AroA) vaccine expressing a major leishmania surface protein (gp63) preferentially induces T helper 1 T cells and protective immunity against leishmaniasis;Yang;J. Immunol,1990